The usefulness of CYFRA 21–1 to diagnose and predict preeclampsia: a nested case-control study

Table 3 Predictive power of maternal serum CYFRA 21–1 levels in symptomatic women with preeclampsia (PE_state) and in asymptomatic women who later developed preeclampsia (PE_long)

Predictor	AUC	95 % CI	Cut-off (ng/ml)	Sensitivity	Specificity	p-value
For existing Preeclampsia (PE_state)
CYFRA 21–1 level at visit:
4	0.85	0.68–1	3.6	0.67	0.96	<0.001
5	0.92	0.85–1	3.1	0.92	0.8	<0.001
6	0.88	0.8–0.97	3.9	0.89	0.77	<0.001
For subsequent Preeclampsia (PE_long)
CYFRA 21–1 level at visit:
1	0.28	0.02–0.53	ND^a	ND	ND	0.088
2	0.51	0.29–0.74	2.5	0.44	0.7	0.909
3	0.54	0.3–0.77	2.8	0.22	0.9	0.785
4	0.71	0.51–0.9	2.1	0.88	0.53	0.037
5	0.70	0.55–0.86	2.4	1	0.51	0.012
6	0.69	0.48–0.9	2.7	1	0.34	0.074
CYFRA 21–1 increase between visits:
1 and 2	0.46	0.24–0.68	ND	ND	ND	0.724
2 and 3	0.48	0.25–0.71	ND	ND	ND	0.857
3 and 4	0.61	0.41–0.81	0.6	0.67	0.94	0.287
4 and 5	0.66	0.51–0.82	0.6	0.83	0.76	0.042
5 and 6	0.69	0.48–0.9	2.0	0.67	0.85	0.074

^aCut-off values, sensitivity, and specificity are not provided if the AUC is <0.5
AUC area under the curve, 95 % CI 95 % confidence interval, CYFRA 21–1 Cytokeratin fragment 21–1, PE preeclampsia

ISSN: 1471-2393